Search / Trial NCT00000790

Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of October 18, 2024

Completed

Keywords

Acquired Immunodeficiency Syndrome Aids Related Complex Thalidomide Stomatitis, Aphthous

Description

Aphthous ulcers of the mouth or esophagus can interfere with eating, resulting in malnutrition and wasting. Thalidomide has been proposed as an effective therapy for severe forms of aphthous ulceration in AIDS patients. Patients are randomized to receive 4 weeks of either thalidomide or placebo orally, administered once daily. Patients are followed weekly. Complete responders after 4 weeks of acute treatment enter a 24-week maintenance phase. A pharmacokinetic substudy will be included.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • * Anti-HIV therapy provided therapy has remained constant in the 4 weeks prior to study entry.
  • * Narcotic analgesia after the first week of treatment ONLY IF the patient is not experiencing somnolence.
  • Patients must have:
  • * Documented HIV infection or AIDS.
  • * Biopsy-confirmed aphthous ulceration of the mouth or esophagus lasting at least 2 weeks.
  • * Negative culture of ulcer for Herpes simplex.
  • * En face diameter of \>= 5 mm for largest aphthous ulcer.
  • * Life expectancy of at least 3 months.
  • NOTE:
  • * This study is approved for prisoner participation.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • * Known allergy to thalidomide.
  • * Grade 2 or worse bilateral peripheral neuropathy.
  • EXCLUDED FOR MAINTENANCE PHASE:
  • * Toxicity other than somnolence in acute phase that required discontinuation of drug.
  • Concurrent Medication:
  • Excluded:
  • * Acute therapy for opportunistic infection.
  • * ddC.
  • * Pentoxifylline.
  • * Methotrexate, trimetrexate, antineoplastic alkylating agents.
  • * Other putative immunomodulators.
  • * CNS depressants and/or medications with sedative or hypnotic effect.
  • * Systemic and/or oral topical corticosteroids.
  • * Systemic chemotherapy for Kaposi's sarcoma or other malignancies.
  • * Compounded antibacterial mouthwashes containing anti-infective agents (such as doxycycline, minocycline, tetracycline, or nystatin).
  • Concurrent Treatment:
  • Excluded:
  • * Radiation to head and/or neck.
  • Patients with the following prior conditions are excluded:
  • * History of grade 2 or worse bilateral peripheral neuropathy.
  • * Change in anti-HIV therapy within 4 weeks prior to study entry.
  • * Prior enrollment in ACTG 251 or prior treatment of aphthous ulcers with thalidomide.
  • Prior Medication:
  • Excluded:
  • * Systemic and/or oral topical corticosteroids within 1 week prior to first set of bloods drawn.
  • * Other putative immunomodulators within 2 weeks prior to study entry.
  • * Prior thalidomide for aphthous ulcers.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Birmingham, Alabama, United States

Los Angeles, California, United States

Indianapolis, Indiana, United States

Bronx, New York, United States

Bronx, New York, United States

Bronx, New York, United States

Bronx, New York, United States

New York, New York, United States

New York, New York, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Seattle, Washington, United States

Chicago, Illinois, United States

New York, New York, United States

New York, New York, United States

Chapel Hill, North Carolina, United States

Cleveland, Ohio, United States

San Francisco, California, United States

Torrance, California, United States

Washington, District Of Columbia, United States

Miami, Florida, United States

Honolulu, Hawaii, United States

Honolulu, Hawaii, United States

Chicago, Illinois, United States

Boston, Massachusetts, United States

Bronx, New York, United States

Bronx, New York, United States

Bronx, New York, United States

Buffalo, New York, United States

Syracuse, New York, United States

Philadelphia, Pennsylvania, United States

Nashville, Tennessee, United States

San Juan, , Puerto Rico

San Francisco, California, United States

Denver, Colorado, United States

Boston, Massachusetts, United States

Bronx, New York, United States

Hershey, Pennsylvania, United States

Chicago, Illinois, United States

Bronx, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0